These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients. Takada K, Toyokawa G, Okamoto T, Shimokawa M, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F, Oda Y, Maehara Y. Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951 [Abstract] [Full Text] [Related]
14. Association between PD-L1 expression and initial brain metastasis in patients with non-small cell lung cancer and its clinical implications. Lee K, Choi YJ, Kim JS, Kim DS, Lee SY, Shin BK, Kang EJ. Thorac Cancer; 2021 Aug; 12(15):2143-2150. PubMed ID: 34121347 [Abstract] [Full Text] [Related]
17. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. Brody R, Zhang Y, Ballas M, Siddiqui MK, Gupta P, Barker C, Midha A, Walker J. Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596 [Abstract] [Full Text] [Related]
18. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens. Heymann JJ, Bulman WA, Swinarski D, Pagan CA, Crapanzano JP, Haghighi M, Fazlollahi L, Stoopler MB, Sonett JR, Sacher AG, Shu CA, Rizvi NA, Saqi A. Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471 [Abstract] [Full Text] [Related]
20. Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer. Zhou C, Che G, Zheng X, Qiu J, Xie Z, Cong Y, Pei X, Zhang H, Sun H, Ma H. J Cancer Res Clin Oncol; 2019 Nov; 145(11):2663-2674. PubMed ID: 31541338 [Abstract] [Full Text] [Related] Page: [Next] [New Search]